- Jazz Pharmaceuticals (JAZZ, Financial) to announce Q1 2025 financial results on May 6, 2025.
- Live audio webcast scheduled at 4:30 p.m. ET for financial discussion and updates.
- Company focused on sleep disorders, epilepsy, and cancer treatment therapies.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is set to release its financial results for the first quarter of 2025 on Tuesday, May 6, 2025, following the closure of the U.S. financial markets. This announcement will be accompanied by a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST, where the company management will discuss the results and provide business updates.
Headquartered in Dublin, Ireland, Jazz Pharmaceuticals is a global biopharmaceutical firm dedicated to developing transformative medicines for serious diseases. Their portfolio includes therapies for sleep disorders, epilepsy, and cancer treatments, focusing on addressing conditions with limited or no existing therapeutic options.
The webcast will be accessible through the Investors section of Jazz Pharmaceuticals' website. Participants are encouraged to register at least 15 minutes before the scheduled start time to ensure a smooth connection. Additionally, a replay of the webcast will be made available post-event via the same webpage.
For more detailed information on how to join the webcast or to access global dial-in numbers, interested parties can visit the company’s official investor relations page. With a strong emphasis on oncology and neuroscience, Jazz Pharmaceuticals continues to expand its robust pipeline of innovative therapeutics worldwide.
